Abstracts tagged "pediatric rheumatology and remission"

Abstract Number: 2858 • 2017 ACR/ARHP Annual Meeting
Validation of Biomarkers to Predict Flare in Polyarticular JIA upon Stopping Anti-TNF Therapy
Daniel J Lovell¹, Sarah Ringold² and P. Scott Eastman³, ¹PRCSG, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH, ²Seattle Children's Hospital, Seattle, WA, ³Senior Director, New Product Development, Crescendo Bioscience, South San Francisco, CA
Background/Purpose: More than 40% of children with polyarticular forms of Juvenile Idiopathic Arthritis (JIA) experience clinical inactive disease on medication (CR). No clinical variable or…
Abstract Number: 1262 • 2013 ACR/ARHP Annual Meeting
Comparison Of Remission Rates For Pediatric Membranous Plus Proliferative Lupus Nephritis Versus Isolated Proliferative Lupus Nephritis: An Analysis Of The Childhood Arthritis and Rheumatism Research Alliance Registry
Alexis Boneparth¹, Norman T. Ilowite¹ and The CARRA Registry Investigators², ¹Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ²Duke Clinical Research Institute, Durham, NC
Background/Purpose: Lupus nephritis (LN) affects many patients with pediatric systemic lupus erythematosus (pSLE) and is a significant cause of disease morbidity. Inability to achieve remission…
Abstract Number: 790 • 2013 ACR/ARHP Annual Meeting
Predictors and Sustainability Of Clinical Inactive Disease In Polyarticular Juvenile Idiopathic Arthritis Given Aggressive Therapy Very Early In The Disease Course
Carol A. Wallace¹, Edward H. Giannini², Steven J. Spalding³, Philip J. Hashkes⁴, Kathleen M. O'Neil⁵, Andrew S. Zeft⁶, Ilona S. Szer⁷, Sarah Ringold⁸, Hermine Brunner⁹, Laura E. Schanberg¹⁰, Robert P. Sundel¹¹, Diana Milojevic¹², Marilynn G. Punaro¹³, Peter Chira¹⁴, Beth S. Gottlieb¹⁵, Gloria C. Higgins¹⁶, Norman T. Ilowite¹⁷, Yukiko Kimura¹⁸, Anne Johnson⁹, Bin Huang¹⁹ and Daniel J. Lovell², ¹University of Washington School of Medicine and Seattle Children's Hospital, Seattle, WA, ²Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³Pediatric Institute, Department of Pediatric Rheumatology, The Cleveland Clinic, Cleveland, OH, ⁴Pediatrics, Shaare-Zedek Medical Center, Jerusalem, Israel, ⁵Pediatric Rheumatology, Riley Hospital for Children, Indianapolis, IN, ⁶Pediatric Institute, Department of Pediatric Rheumatology, Cleveland Clinic Foundation, Cleveland, OH, ⁷Div of Rheumatology, Rady Childrens Hosp San Diego, San Diego, CA, ⁸Pediatrics, Seattle Children's Hospital/Univ of Washington, Seattle, WA, ⁹Pediatric Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ¹⁰Pediatrics, Duke University Medical Center, Durham, NC, ¹¹Division of Immunology, Boston Children's Hospital, Boston, MA, ¹²Dept of Pediatric Rheumatology, University of California, San Francisco, San Francisco, CA, ¹³Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹⁴Pediatric Rheumatology, Indiana University School of Medicine, Riley Hospital for Children, Indianapolis, IN, ¹⁵Pediatric Rheumatology, Cohen Children's Medical Center of New York, New Hyde Park, NY, ¹⁶Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ¹⁷Pediatrics, The Children's Hospital at Montefiore, Bronx, NY, ¹⁸Pediatric Rheumatology, Joseph M Sanzari Children’s Hospital, Hackensack University Medical Center, Hackensack, NJ, ¹⁹Biostatistics and Epidemiology, Cincinnati Children's Hospital Medical Center/University of Cincinnati School of Medicine, Cincinnati, OH
Background/Purpose: The double-blind, randomized placebo-controlled Trial of Early Aggressive Therapy in Polyarticular Juvenile Idiopathic Arthritis (TREAT) compared the ability of 2 aggressive treatment regimens to…
Abstract Number: 1021 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging in Follow-up of Clinical Remission in Juvenile Idiopathic Arthritis
Mira van Veenendaal¹, Robert Hemke², Marjolein I. Bos³, Mario Maas⁴, Marion A. J. Van Rossum³ and Taco W. Kuijpers⁵, ¹Departments of Pediatric Rheumatology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ²Departments of Radiology, Academic Medical Center (AMC), Amsterdam, Netherlands, ³Department of Pediatric Rheumatology and Immunology, Emma Children's Hospital / Academic Medical Center (AMC), Amsterdam, Netherlands, ⁴Radiology, Academic Medical Center, Amsterdam, Netherlands, ⁵Pediatric Rheumatology and Immunology, Emma Children's Hospital/Academic Medical Center (AMC), Amsterdam, Netherlands
Background/Purpose: Despite clinical remission, a substantial proportion of Juvenile Idiopathic Arthritis (JIA) patients will flare after a period of inactive disease. MRI has proven to…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].